Stockreport

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – On track to announce top-line results from Phase 2 CANYON trial of sevasemten in adults with Becker in December 2024 –– Advanced Phase 2 LYNX and FOX trials of sevasem [Read more]